What exciting updates on maintenance therapy in AML were presented at ASH 2023?

At the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, Gail Roboz, Weill Cornell Medicine, New York, US, shared her insights with the AML Hub. We asked “What exciting updates on maintenance therapy in acute myeloid leukemia were presented at ASH 2023?”

Roboz discusses the use of oral azacitidine as a maintenance therapy for patients with acute myeloid leukemia, highlighting results from the QUAZAR AML-001 trial, before exploring the impact of maintenance therapy on measurable residual disease status and postremission outcomes. She reviews the optimal selection of maintenance therapies, and how measurable residual disease status can influence treatment decisions in subgroups such as NPM1-mutated and FLT3-mutated AML. Roboz concludes by emphasizing the need for more randomized clinical trials evaluating maintenance therapies and considers future directions, including menin inhibitors and high-sensitivity measurable residual disease testing.